54 related articles for article (PubMed ID: 25900861)
1. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.
Dignam JJ; Dukic V; Anderson SJ; Mamounas EP; Wickerham DL; Wolmark N
Breast Cancer Res Treat; 2009 Aug; 116(3):595-602. PubMed ID: 18830816
[TBL] [Abstract][Full Text] [Related]
2. Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study.
Guerrieri-Gonzaga A; Lazzeroni M; Botteri E; Serrano D; Rotmensz N; Varricchio MC; Cazzaniga M; Bollani G; Mora S; Montefrancesco C; Pruneri G; Viale G; Intra M; Galimberti V; Goldhirsch A; Bagnardi V; Bonanni B; DeCensi A
Ann Oncol; 2013 Jul; 24(7):1859-1866. PubMed ID: 23532115
[TBL] [Abstract][Full Text] [Related]
3. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Dowsett M; Sestak I; Regan MM; Dodson A; Viale G; Thürlimann B; Colleoni M; Cuzick J
J Clin Oncol; 2018 Jul; 36(19):1941-1948. PubMed ID: 29676944
[TBL] [Abstract][Full Text] [Related]
4. 17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer.
Sivik T; Gunnarsson C; Fornander T; Nordenskjöld B; Skoog L; Stål O; Jansson A
PLoS One; 2012; 7(7):e40568. PubMed ID: 22792371
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study.
Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Piper T; Salunga RC; Ahmed I; Doos L; Thornber S; Taylor KJ; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
Clin Cancer Res; 2022 May; 28(9):1871-1880. PubMed ID: 35144966
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients.
Villasco A; Accomasso F; D'Alonzo M; Agnelli F; Sismondi P; Biglia N
Breast Cancer; 2021 Sep; 28(5):1131-1140. PubMed ID: 33939116
[TBL] [Abstract][Full Text] [Related]
7. Insights adjusting for non-adherence in randomized clinical trials: a reanalysis of an adjuvant trial of tamoxifen duration in early breast cancer.
Giudici F; Pistilli B; Vaz-Luis I; Karimi M; Delaloge S; Bachelot T; Michiels S; Bardet A
Br J Cancer; 2023 Oct; 129(9):1516-1523. PubMed ID: 37697030
[TBL] [Abstract][Full Text] [Related]
8. Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers.
Wahdan-Alaswad RS; Edgerton SM; Salem H; Kim HM; Tan AC; Finlay-Schultz J; Wellberg EA; Sartorius CA; Jacobsen BM; Haugen BR; Liu B; Thor AD
Clin Cancer Res; 2021 Jan; 27(2):585-597. PubMed ID: 33097494
[TBL] [Abstract][Full Text] [Related]
9. Validation of the Prognostic Performance of Breast Cancer Index in Hormone Receptor-Positive Postmenopausal Breast Cancer Patients in the TEAM Trial.
Bartlett JMS; Xu K; Wong J; Pond G; Zhang Y; Spears M; Salunga R; Mallon E; Taylor KJ; Hasenburg A; Markopoulos C; Dirix L; van de Velde CJH; Rea D; Schnabel CA; Treuner K; Bayani J
Clin Cancer Res; 2024 Apr; 30(8):1509-1517. PubMed ID: 38345755
[TBL] [Abstract][Full Text] [Related]
10. Women with Breast Cancer Can Attempt Pregnancy.
Cancer Discov; 2023 Jul; 13(7):1504-1505. PubMed ID: 37199496
[TBL] [Abstract][Full Text] [Related]
11. Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA.
Spano JP; Beuzeboc P; Coeffic D; Arnould L; Lortholary A; Andre F; Ferrero JM
Breast; 2015 Aug; 24(4):376-83. PubMed ID: 25913287
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
Earl HM; Hiller L; Dunn JA; Blenkinsop C; Grybowicz L; Vallier AL; Abraham J; Thomas J; Provenzano E; Hughes-Davies L; Gounaris I; McAdam K; Chan S; Ahmad R; Hickish T; Houston S; Rea D; Bartlett J; Caldas C; Cameron DA; Hayward L;
Lancet Oncol; 2015 Jun; 16(6):656-66. PubMed ID: 25975632
[TBL] [Abstract][Full Text] [Related]
13. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.
Despierre E; Vergote I; Anderson R; Coens C; Katsaros D; Hirsch FR; Boeckx B; Varella-Garcia M; Ferrero A; Ray-Coquard I; Berns EM; Casado A; Lambrechts D; Jimeno A; ; ; ; ; ;
Target Oncol; 2015 Dec; 10(4):583-96. PubMed ID: 26004768
[TBL] [Abstract][Full Text] [Related]
14. Detection of a negative correlation between prescription of Chinese herbal products containing coumestrol, genistein or daidzein and risk of subsequent endometrial cancer among tamoxifen-treated female breast cancer survivors in Taiwan between 1998 and 2008: A population-based study.
Hu YC; Wu CT; Lai JN; Tsai YT
J Ethnopharmacol; 2015 Jul; 169():356-62. PubMed ID: 25934515
[TBL] [Abstract][Full Text] [Related]
15. Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival.
Kwan ML; Bernard PS; Kroenke CH; Factor RE; Habel LA; Weltzien EK; Castillo A; Gunderson EP; Maxfield KS; Stijleman IJ; Langholz BM; Quesenberry CP; Kushi LH; Sweeney C; Caan BJ
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25921910
[TBL] [Abstract][Full Text] [Related]
16. Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.
Elebro K; Borgquist S; Simonsson M; Markkula A; Jirström K; Ingvar C; Rose C; Jernström H
Clin Cancer Res; 2015 Aug; 21(16):3640-50. PubMed ID: 25904752
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Status in Iran: Statistical Analysis of 3010 Cases between 1998 and 2014.
Akbari ME; Sayad S; Sayad S; Khayamzadeh M; Shojaee L; Shormeji Z; Amiri M
Int J Breast Cancer; 2017; 2017():2481021. PubMed ID: 29201466
[TBL] [Abstract][Full Text] [Related]
18. Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years.
Wu CE; Chen SC; Chang HK; Lo YF; Hsueh S; Lin YC
J Formos Med Assoc; 2016 Apr; 115(4):249-56. PubMed ID: 25900861
[TBL] [Abstract][Full Text] [Related]
19. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
